Serum Institute develops first indigenous vaccine against pneumonia; to be launched next week – ET HealthWorldDecember 24, 2020
According to the sources, the vaccine will be rather more inexpensive than the present ones manufactured by two international corporations.
India’s drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the part 1, 2 and three medical trial knowledge submitted by the Pune-based agency.
This vaccine is used for energetic immunisation against invasive illness and pneumonia attributable to “Streptococcus pneumonia” in infants, the well being ministry had stated earlier.
Serum Institute has performed the part 1, 2 and three medical trials of the vaccine in India and African nation Gambia.
“This is the first indigenously developed vaccine in the field of pneumonia,” an official supply stated.
The vaccine will be rather more inexpensive than the present ones produced by Pfizer (NYSE: PFE) and GlaxoSmithKline (LSE: GSK), the sources stated.
“It has always been our endeavour to fulfil our prime minister’s dream for ‘vocal for local’ and ‘Making in India’ for the world.
“Moving in direction of prime minister’s clarion name of Atmanirbhar Bharat, now we have achieved yet another historic milestone through the lockdown interval of Covid-19 pandemic by growing India’s first world-class indigenous pneumococcal conjugate vaccine (PCV) and obtained Indian licensure,” stated a letter written by Prakash Kumar Singh, Additional Director, Government and Regulatory Affairs at the Serum Institute of India (SII) addressed to Vardhan.
As per UNICEF data, more than one lakh children under the age of five years die every year in India due to the pneumococcal disease.
Since pneumonia is a respiratory ailment, vaccination of children with the pneumococcal conjugate vaccines (PCV) assumes utmost significance during the current Covid-19 pandemic, an official source said.
The country is currently dependent on imported PCV of foreign manufacturers at a very high price, the source said.
The vaccine which is administered in an intramuscular manner was prequalified by the WHO in January.
Earlier, the demand of such vaccine was substantially met by licensed importers in the country since the manufacturers were all vaccine companies based outside India, the health ministry had earlier said.
(This story has not been edited by Newslivenation workers and is auto-generated from a syndicated feed.)